<DOC>
	<DOCNO>NCT01850849</DOCNO>
	<brief_summary>The principle aim study obtain safety , tolerability pharmacokinetic data LEO 39652 cream administer cutaneously single dose subject atopic dermatitis healthy subject .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics AD Subjects Healthy Subjects Cutaneous Application LEO 39652 Cream</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Healthy subject subject AD define Hanifen Rajka criterion least mild disease activity ( IGA &gt; 2 ) whole body AD lesion amenable cutaneous treatment locate trunk and/or limb ( AD subject ) Male subject age 18 65 year body mass index ( BMI ) 19.0 32.0 kg/m2 inclusive Subjects currently suffer , show sign eczema skin lesion ( healthy subject ) Subjects still participate clinical trial ( e.g . attend followup visit ) participate clinical study involve administration investigational product market drug product within past 3 month prior first dose occasion . Subjects know immunocompromised state due treatment immunosuppressive drug due history disease lead immunocompromised status . History current cardiac arrhythmic disorder Subjects current active malignancy history malignancy remission le 5 year except excised skin ( melanoma ) cervical cancer . Subjects clinically significant allergic disease ( exclude non active hayfever ) determine Investigator</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>